Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
Total Valuation
Gyre Therapeutics has a market cap or net worth of $669.39M. The enterprise value is $739.30M.
Market Cap$669.39M
Enterprise Value$739.30M
Share Statistics
Gyre Therapeutics has 90,826,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding90,826,775
Owned by Insiders3.88%
Owned by Institutions<0.01%
Financial Efficiency
Gyre Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 11.61%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)11.61%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee182.65K
Profits Per Employee30.91K
Employee Count579
Asset Turnover0.84
Inventory Turnover0.61
Valuation Ratios
The current PE Ratio of Gyre Therapeutics is 447.2. Gyre Therapeutics’s PEG ratio is ―.
PE Ratio447.2
PS Ratio―
PB Ratio―
Price to Fair Value16.26
Price to FCF―
Price to Operating Cash Flow741.22
PEG Ratio―
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of 105.76M and earned 12.09M in profits. Earnings per share was 0.14.
Revenue105.76M
Gross Profit101.87M
Operating Income16.16M
Pretax Income23.22M
Net Income12.09M
EBITDA17.82M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was 927.00K and capital expenditures -1.01M, giving a free cash flow of -79.00K billion.
Operating Cash Flow927.00K
Free Cash Flow-79.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Gyre Therapeutics pays an annual dividend of $3.6, resulting in a dividend yield of ―
Dividend Per Share$3.6
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change-43.05%
50-Day Moving Average7.59
200-Day Moving Average9.28
Relative Strength Index (RSI)45.09
Average Volume (3m)103.43K
Important Dates
Gyre Therapeutics upcoming earnings date is Nov 12, 2025, TBA (Confirmed).
Last Earnings DateAug 11, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend DateJan 13, 2023
Financial Position
Gyre Therapeutics as a current ratio of 3.32, with Debt / Equity ratio of 1.51%
Current Ratio3.32
Quick Ratio2.99
Debt to Market Cap<0.01
Net Debt to EBITDA-0.57
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gyre Therapeutics has paid 5.32M in taxes.
Income Tax5.32M
Effective Tax Rate0.23
Enterprise Valuation
Gyre Therapeutics EV to EBITDA ratio is 57.22, with an EV/FCF ratio of -171.16.
EV to Sales9.64
EV to EBITDA57.22
EV to Free Cash Flow-171.16
EV to Operating Cash Flow-279.99
Balance Sheet
Gyre Therapeutics has $36.49M in cash and marketable securities with $1.39M in debt, giving a net cash position of $35.10M billion.
Cash & Marketable Securities$36.49M
Total Debt$1.39M
Net Cash$35.10M
Net Cash Per Share$0.39
Tangible Book Value Per Share$1.15
Margins
Gross margin is 95.91%, with operating margin of 15.28%, and net profit margin of 11.43%.
Gross Margin95.91%
Operating Margin15.28%
Pretax Margin21.95%
Net Profit Margin11.43%
EBITDA Margin16.85%
EBIT Margin15.35%
Analyst Forecast
The average price target for Gyre Therapeutics is $21.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.67
Price Target Upside197.26% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―